Abstract: Peptides that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.

Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.

Abstract: Cyclized peptides derived from the hyaluronan binding region of RHAMM are provided. Pharmaceutical compositions and methods for using the peptides and pharmaceutical compositions are also provided. The peptides and pharmaceutical compositions can be used for the treatment of cancer, inflammatory disorders, autoimmune disorders, and fibrotic disorders.

Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.

Abstract: Cyclized peptides derived from the hyaluronan binding region of RHAMM are provided. Pharmaceutical compositions and methods for using the peptides and pharmaceutical compositions are also provided.

Abstract: The present invention relates to topical glycosaminoglycan compositions, particularly hyaluronan compositions, that facilitate the penetration of modified glycosaminoglycans through the skin barrier into the epidermal and dermal layers of the skin, thereby allowing for the dermal administration of a glycosaminoglycan, such as hyaluronan, without requiring an injection. Through their ability to deliver hyaluronan to the epidermal and dermal layers, the present formulations are therefore suitable for use in dermal rejuvenation, enhancement, hyaluronan replenishment and protection therapy. The glycosaminoglycan compositions are also useful as delivery devices to facilitate the dermal and transdermal delivery of cosmetically and pharmaceutically active substances, including pharmaceuticals, polypeptides, proteins and similarly sized biomacromolecules, through the skin barrier.

Abstract: Peptides that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.

Abstract: Cyclized peptides derived from the hyaluronan binding region of RHAMM are provided. Pharmaceutical compositions and methods for using the peptides and pharmaceutical compositions are also provided.

Abstract: The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression.

Abstract: CD44 is an integral hyaluronan receptor that can either promote or inhibit motogenic signaling in tumor cells. Rhamm is a non-integral cell surface (CD168) and intracellular hyaluronan binding protein that promotes cell motility in vitro and whose expression is strongly upregulated in aggressive tumors. The present invention describes compositions and methods for the prognosis and diagnosis of cancer by the detection of CD44/Rhamm complexes. The use of labeled Rhamm-binding agents in culture and in vivo to identify tumorigenic progenitor cells that exhibit an aggressive phenotype characterized by high Rhamm and CD44 expression is further described. Specific methods include using hyaluronan to target imaging or therapeutic agents to these progenitor tumor subsets in breast and likely other cancers.

Abstract: The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression.

Abstract: The present invention relates to topical glycosaminoglycan compositions, particularly hyaluronan compositions, that facilitate the penetration of modified glycosaminoglycans through the skin barrier into the epidermal and dermal layers of the skin, thereby allowing for the dermal administration of a glycosaminoglycan, such as hyaluronan, without requiring an injection. Through their ability to deliver hyaluronan to the epidermal and dermal layers, the present formulations are therefore suitable for use in dermal rejuvenation, enhancement, hyaluronan replenishment and protection therapy. The glycosaminoglycan compositions are also useful as delivery devices to facilitate the dermal and transdermal delivery of cosmetically and pharmaceutically active substances, including pharmaceuticals, polypeptides, proteins and similarly sized biomacromolecules, through the skin barrier.

Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.

Abstract: The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression.

Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.

Abstract: Herein is described the methods and compositions for modulation of Rhamm, also known as CD 186, and its effects on wound repair, muscle differentiation, bone density and adipogeneisis through its ability to regulate mesenchymal stem cell differentiation. Compositions and methods are provided for blocking Rhamm function for selectively increasing subcutaneous, but not, visceral fat. Compositions and methods for modulating Rhamm in wound repair are also described.

Abstract: Methods are provided for the rapid and robust screening test agents for adipogenic activity. Agents testing positive in the assays are good candidate agents for wrinkle reduction, normalizing skin appearance after reconstructive or cosmetic surgery, e.g., grafted tissue on burn victims, normalizing skin appearance during and after wound healing, and the like. In certain embodiments the methods involve providing mammalian test cells with adipogenic potential wherein said cells are primed for, but withheld from differentiation into adipocytes; contacting the cells with the test agent(s); and screening said test cells for an adipocyte phenotype wherein the presence of a feature characteristic of an adipocyte is an indicator that said test agent is adipogenic.

Abstract: The present invention provides for peptides that bind to Receptor for Hyaluronic Acid Mediated Motility (RHAMM) molecules. More specifically, provided are peptides capable of specifically binding RHAMM molecules and capable of binding RHAMM with substantially high affinity. These novel RHAMM-binding peptides provide the basis for new imaging probes that can be used to identify cells expressing RHAMM, and for methods of imaging, prognosis, diagnosis and treatment of conditions associated with RHAMM expression.

Abstract: The present invention relates to topical glycosaminoglycan compositions, particularly hyaluronan compositions, that facilitate the penetration of modified glycosaminoglycans through the skin barrier into the epidermal and dermal layers of the skin, thereby allowing for the dermal administration of a glycosaminoglycan, such as hyaluronan, without requiring an injection. Through their ability to deliver hyaluronan to the epidermal and dermal layers, the present formulations are therefore suitable for use in dermal rejuvenation, enhancement, hyaluronan replenishment and protection therapy. The glycosaminoglycan compositions are also useful as delivery devices to facilitate the dermal and transdermal delivery of cosmetically and pharmaceutically active substances, including pharmaceuticals, polypeptides, proteins and similarly sized biomacromolecules, through the skin barrier.

Abstract: Compositions comprising hyaluronic acid (HA) or agents that interfere with HA binding of HA receptors and methods of using the same are provided. For example, there is provided a composition comprising HA oligomers ranging in size from 10-mer to 80-mer and use of the same for promoting migration, growth or survival of wild-type or transformed/cancerous cells. There is also provided a composition comprising an agent that interferes with binding between an HA oligomer of a size of about 10-mer to about 80-mer and an HA receptor. Such compositions may be useful for therapeutic, diagnostic or imaging applications. Examples of therapeutic use are wound repair or cancer treatment.